4FZ7
Crystal structure of spleen tyrosine kinase complexed with 6-((1R,2S)-2-Amino-cyclohexylamino)-4-(6-ethyl-pyridin-2-ylamino)-pyridazine-3-carboxylic acid amide
Summary for 4FZ7
Entry DOI | 10.2210/pdb4fz7/pdb |
Related | 3FQE |
Descriptor | Tyrosine-protein kinase SYK, 6-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(6-ethylpyridin-2-yl)amino]pyridazine-3-carboxamide (3 entities in total) |
Functional Keywords | kinase inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 34239.44 |
Authors | Kuglstatter, A.,Slade, M. (deposition date: 2012-07-06, release date: 2013-07-10, Last modification date: 2023-09-13) |
Primary citation | Lucas, M.C.,Bhagirath, N.,Chiao, E.,Goldstein, D.M.,Hermann, J.C.,Hsu, P.Y.,Kirchner, S.,Kennedy-Smith, J.J.,Kuglstatter, A.,Lukacs, C.,Menke, J.,Niu, L.,Padilla, F.,Peng, Y.,Polonchuk, L.,Railkar, A.,Slade, M.,Soth, M.,Xu, D.,Yadava, P.,Yee, C.,Zhou, M.,Liao, C. Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors. J. Med. Chem., 57:2683-2691, 2014 Cited by PubMed: 24520947DOI: 10.1021/jm401982j PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.75 Å) |
Structure validation
Download full validation report